Despite advances in targeted cancer therapies, there is an unmet need for new screening tools to rapidly match the patient with the best treatment in order to avoid severe adverse events that can be associated with new therapies. Autoantibodies may provide a solution.
Cancer cells can induce an immunological response resulting in the production of autoantibodies against tumor-associated antigens. These autoantibodies reflect the humoral immune response against a tumor and can be detected at an early stage, sometimes before the development of clinical symptoms.
Autoantibody signatures can be used to stratify treatment responders and non-responders and to predict which patients may suffer adverse events.